Drug intelligence / Profile preview

ACNU + lymphokine-activated killer cells + interferon beta

Development stage: Unknown
Lead developer: St. Luke's Medical Center
Modality: Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Intrathecal, Intratumoral, Intracavitary, Intra-arterial

Overview

A combination therapy consisting of ACNU (nimustine, a nitrosourea chemotherapy agent), lymphokine-activated killer (LAK) cells (cytolytic lymphocytes activated by IL-2), and interferon beta. This multi-modal approach combines direct cytotoxic effects on tumor cells through DNA alkylation and cross-linking (ACNU), cellular immunotherapy (LAK cells), and immune system modulation (interferon beta).

Targets

ULBP1 (UL16-binding protein 1)IFNAR (Immune system modulation via type I interferon receptor)DNA

Beyond the preview

Go deeper on ACNU + lymphokine-activated killer cells + interferon beta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACNU + lymphokine-activated killer cells + interferon beta.

Explore the full profile